Course curriculum
-
-
Acanthosis nigricans (September 2021)
-
ACE inhibitor and ARB use in diabetes (July 2018)
-
Acid-base disorders (November 2018)
-
Acromegaly - 2Qs (May 2023)
-
Acute gout - 2Qs (May 2021)
-
Acute pancreatitis (March 2019)
-
Addisons disease - 2Qs (May 2021)
-
Adnexal mass in premenopausal women - 2Qs (November 2019)
-
Alcohol use disorder (July 2018)
-
Alcohol use disorder evaluation (July 2018)
-
Alcohol use disorder - treatment (November 2022)
-
Alcohol withdrawal - 4Qs (January 2020)
-
Amenorrhea - Secondary - 2Qs (September 2018)
-
Amyloidosis (March 2019)
-
Aspirin therapy and diabetes (May 2019)
-
Aspirin therapy in diabetics (September 2021)
-
Bariatric surgery - 2Qs (March 2019)
-
Bisphosphonate management (September 2020)
-
Bone mineral density testing (January 2022)
-
Central sleep apnea (January 2023)
-
Cervical adenopathy (May 2023)
-
Chronic kidney disease - 2Qs (May 2022)
-
Chronic pancreatitis - 3Qs (January 2022)
-
Compression fractures (November 2019)
-
Contraception and neurologic disease - 2Qs (March 2019)
-
Cushing Syndrome - 2Qs (May 2022)
-
Diabetes - Journal Club - 5Qs (January 2023)
-
Diabetes - adding insulin - 2Qs (March 2022)
-
Diabetes and chronic kidney disease - 3Qs (July 2021)
-
Diabetes in children (November 2020)
-
Diabetes - Diagnosis (September 2018)
-
Diabetes - Individualization of medications - 3Qs (November 2019)
-
Diabetes - Perioperative management (May 2020)
-
Diabetic kidney disease - 2Qs (March 2022)
-
Diabetes - screening in pregnancy (September 2019)
-
Diabetes - Type 1 in children - 3Qs (September 2020)
-
Diabetes mellitus - Type 1 Pediatric- 2Qs (January 2020)
-
Diabetes - Type 2 in children and adolescents - 3Qs (September 2019)
-
Diabetes mellitus type 2 – prevention - 3Qs (May 2019)
-
Diabetic autonomic neuropathy - 2Qs (July 2021)
-
Diabetic foot osteomyelitis - 3Qs (May 2020)
-
Diabetic ketoacidosis - 4 Qs (July 2021)
-
Diabetic ketoacidosis and euglycemia - 2Qs (January 2020)
-
Diabetic retinopathy - 2Qs (January 2022)
-
Dysmenorrhea - 2Qs (January 2023)
-
Elevated ammonia level - 2Qs (March 2022)
-
G6PD deficiency - 5Qs (March 2021)
-
Galactorrhea (January 2022)
-
Gastroparesis (UPDATED) - 3Qs (May 2020)
-
Gastroparesis - 3Qs (September 2018)
-
Gestational diabetes - 4Qs (September 2018)
-
Gestational diabetes - screening - 2Qs (November 2021)
-
Gluten sensitivity - 3Qs (March 2021)
-
Glycemic control - 3Qs (May 2019)
-
Gout - 4Qs (September 2020)
-
Gout prevention - 3Qs (November 2022)
-
Graves disease - 2Qs (July 2020)
-
Graves disease (September 2018)
-
Gynecomastia (July 2022)
-
Gynecomastia - 3Qs (September 2019)
-
Heat-related illness -3Qs (January 2021)
-
Hemoglobin A1c targets - 3Qs (September 2021)
-
Hemoglobin A1C targets (September 2018)
-
Hirsutism in women (November 2019)
-
HIV and long-term comorbidities (July 2022)
-
Hypercalcemia - 5Qs (May 2021)
-
Hyperglycemia -Medication-induced - 2Qs (September 2019)
-
Hyperglycemia - Corticosteroid-induced - 3Qs (November 2019)
-
Hyperosmolar hyperglycemic state - 2Qs (November 2020)
-
Hyperparathyroidism - 2Qs (July 2020)
-
Hyperphosphatemia (January 2021)
-
Hyperphosphatemia - 2Qs (July 2020)
-
Hyperprolactinemia - 2Qs (January 2020)
-
Hyperthyroidism - subclinical (May 2021)
-
Hypertriglyceridemia - 2Qs (July 2021)
-
Hypertriglyceridemia - 2Qs (November 2018)
-
Hypoglycemia - Neonatal (September 2019)
-
Hypomagnesemia - 2Qs (January 2023)
-
Hyponatremia - 2Qs (May 2019)
-
Hypoparathyroidism - 2Qs (November 2019)
-
Incretin-based therapy for type 2 diabetes mellitus (July 2018)
-
Inhalant abuse (January 2023)
-
Intermittent fasting (January 2021)
-
Iron overload disorders - 3Qs (May 2021)
-
Insulin types - 3Qs (July 2021)
-
Lactic acidosis (September 2022)
-
Levothyroxine dosing - 3Qs (March 2022)
-
Levothyroxine drug interactions (January 2022)
-
Lipid screening in children (November 2019)
-
Medication-related fever (September 2022)
-
Menstrual migraine - 2Qs (May 2019)
-
Metformin (September 2021)
-
Minimal change disease (November 2019)
-
Multinodular goiter - 3Qs (January 2021)
-
Multiple endocrine neoplasia - 4Qs (January 2022)
-
Myxedema coma (March 2023)
-
Myxedema coma (May 2022)
-
Nephrolithiasis in children - 2Qs (July 2021)
-
Nephrotic syndrome - 2Qs (January 2019)
-
Nonalcoholic fatty liver disease - 2Qs
-
Non-motor symptoms of Parkinson disease - 4Qs (May 2022)
-
Nutrition and mental health - 2Qs (May 2023)
-
Obesity effect on fertility and pregnancy - 2Qs (November 2022)
-
Opioid-induced endocrinopathy - 2Qs (November 2021)
-
Pancreatitis (November 2022)
-
Painful diabetic neuropathy - 2Qs (May 2022)
-
Pancreatitis - 3Qs (July 2022)
-
Postpartum thyroiditis (July 2020)
-
Prediabetes - 2Qs (November 2021)
-
Prediabetes (November 2018)
-
Prediabetes in adults - 2Qs (May 2020)
-
Pregnancy and obesity (May 2019)
-
Premature ovarian insufficiency - 3Qs (May 2022)
-
Premenstrual syndrome and premenstrual dysphoric disorder - 3Qs (May 2022)
-
Pseudogout (July 2021)
-
Restless legs syndrome - 2Qs
-
Screening for Type 2 Diabetes - 3Qs (January 2022)
-
Secondary dysmenorrhea (January 2023)
-
SIADH - 2Qs (March 2021)
-
Sodium-coupled glucose transporter-2 (SGLT2) inhibitors - 2Qs (March 2019)
-
Statins and diabetes (March 2022)
-
Subclinical hyperthyroidism (July 2018)
-
Sulfonylurea overdose - 2Qs (November 2019)
-
Syndrome of inappropriate antidiuretic hormone (SIADH) - 3Qs (November 2021)
-
Thyroid cancer - 2Qs (July 2022)
-
Thyroid disease in pregnancy - 3Qs (May 2022)
-
Thyroid medication – dosing - 2Qs (May 2019)
-
Tranexamic acid (generic, Lysteda) (March 2019)
-
Transgender health care (March 2019)
-
Type 2 diabetes mellitus - initial management - 3Qs (July 2020)
-
Understanding lipid recommendations - 2Qs (September 2018)
-
Uterine bleeding - Abnormal (September 2018)
-
Uterine bleeding in the adolescent - Abnormal - 3Qs (September 2018)
-
Vitamin B12 deficiency (November 2019)
-
Wilson's disease (March 2019)
-
About this course
- Free
- 135 lessons
- 0 hours of video content